Jacques BOLLEKENS,Salah-Dine CHIBOUT,Jacky VONDERSCHER,Francois LEGAY,Andre CORDIER,Ruben PAPOIAN,Andreas SCHERER
申请号：
US13152750
公开号：
US20120028896A1
申请日:
2011.06.03
申请国别(地区):
US
年份:
2012
代理人:
摘要：
A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.
